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Background: Chronic Obstructive Pulmonary Disease (COPD) is the most common severe chronic disease in primary
care. It is typically diagnosed at a late stage, and it is also difficult to predict its trajectory and hence to tailor treatment
and rehabilitation. The overall aim is to study determinants of exacerbations of COPD treated in primary care and to
study, if the prognosis is related to patient-related, healthcare system markers or levels of the potential biomarkers such
as microfibrillar-associated protein 4 (MFAP4) and surfactant protein D (SP-D). Furthermore, we aim to establish a cohort
of COPD patients treated in Danish primary care comprising register data, data captured from the GPs’ electronic
patient record system (EPR) and a biobank in order to make analyses on factors associated with different tractories of
COPD treated in primary care.
Methods/design: A cohort study of incident and prevalent COPD patients treated and followed by their GPs using
data capture, which is a computer system collecting data from the GPs’ own EPR and transferring them to the Danish
General Practice Research Database. The participating COPD patients were investigated at a baseline consultation by
their own GP, and the results were registered using a pop-up menu by the GP. During the consultation blood samples
were taken and the patients were given a questionnaire. The patients will then be followed prospectively at yearly
consultations and in between these consultations by means of the data capture system. The collected data will
also be combined with register data from other sources. The data collection started in December 2012, and so far
30 practices with 77 GPs have included about 350 patients. The study aims to include 2000 patients till the end
of 2016, and after that to continue to collect data on these patients using the data capture system.
Discussion: The GP currently lacks tools to predict trajectory of their COPD patients. The measurement of lung
function only reflects loss of lung capacity and not disease activity. Use of biomarkers for detection of early COPD
could be a possible way of predicting trajectory to aid both the GP and his/her patients. This study aims to provide
evidence of determinants of a COPD trajectory, including novel specific biomarkers and other patient- and healthcare
system-related markers.
Trial registration: ClinicalTrials.gov Protocol Registration System, Identifier: NCT01698151* Correspondence: anhalling@health.sdu.dk
Research Unit of General Practice, Institute of Public Health, University of
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Chronic obstructive pulmonary disease (COPD) is a com-
mon chronic, often life-threatening disease characterised
by a permanent and progressive airway obstruction.
COPD is clinically defined as having irreversibly reduced
airway function of an obstructive type (FEV1/FVC <70%)
[1-3]. According to the World Health Organisation 80
million people suffer from moderate to severe COPD
worldwide, and it is expected that this will increase to
become the third most important cause of death. It is
estimated that in the population of 5.5 million inhabi-
tants in Denmark, 430 000 people suffer from COPD,
230 000 of these from moderate COPD and 40 000 from
severe COPD [4]. Denmark has one of the highest preva-
lences and mortality rates of COPD, probably primarily
due to frequent tobacco use. Hospital visits for this group
of patients are common and account for a substantial part
of healthcare costs as a whole [5,6]. Some 85% of patients
with COPD are or have been smokers, and it is estimated
that 35-40% of smokers develop the disease [7]. COPD is
associated with a low socioeconomic status, markedly
reduced quality of life, large use of prescribed drugs
and frequent contacts with the healthcare system [2,6,8].
COPD is a progressive disease developing over decades,
but if the degree of disease progression among COPD
patients is not stopped, in 10-15 years there will be an
even greater need for hospital beds, medical treatment
and rehabilitation at huge expenditure.
In Denmark 98% of the population is listed with a GP
who provides primary care for a defined part of the
population. A large part of the population consults their
GP several times during a year. Most COPD patients are
diagnosed by their GP, typically after a long period of
productive cough and reduced function in daily life with
dyspnoea. The maximum prevalence is reached at about
the age of 80 years. Today much of a patient´s lung
function is already lost at the time of diagnosis. Despite
massive preventive measures COPD is a major and ris-
ing problem in Denmark [9]. The diagnosis is made by
investigation of lung function (spirometry), which can be
performed by the GP, but it takes time and requires skill
and is therefore not always performed [10,11]. The
measurement of lung function can, however, neither in
light or moderate COPD predict the development of the
disease, as it only reflects loss of lung capacity and not
disease activity. Exacerbations are associated with signifi-
cant mortality, loss in lung function and deterioration in
quality of life [12-14]. Apart from previous exacerbation
history, we currently have no good tools to identify frequent
exacerbators. Use of biomarkers for detection of early
COPD could be a possible new way [15,16] of predicting
prognosis to aid both the GP and his/her patients, but
until now no biomarkers of disease activity have been
shown to predict a COPD trajectory. However, through anongoing collaboration [17] we have established a working
relationship with specialists in molecular medicine. Two
molecules have especially been in focus for their studies:
surfactant protein D (SP-D) [18,19] and microfibrillar-
associated protein 4 (MFAP4). Lack of either SP-D or
MFAP4 leads to development of emphysema in mice and
could thus be involved in the heterogeneity in disease
development and progression of COPD. Both molecules
are primarily expressed in the lungs, and both molecules
are present in humans. In the ECLIPSE cohort SP-D has
been shown to be associated with exacerbations, but not
with the severity of COPD [18].
Objective
The overall aim is to establish a cohort of COPD patients
in primary care and to study determinants of COPD exac-
erbations related to the patient and the healthcare system.
The aim is also to test the ability of MFAP4 and SP-D as
biomarkers to predict exacerbations, so that treatment
and rehabilitation efforts can be focused on the patient
groups that benefit the most.
Methods and design
Participants
Patients with a diagnosis of COPD (ICPC code R95-) are
eligible for participation, if they are listed with a GP par-
ticipating in the study, are aged ≥ 40 years, understand
Danish, do not have severe psychiatric or cognitive disease
and are able to visit the GP surgery. Participating GPs are
also encouraged to screen for COPD in patients with rele-
vant symptoms or risk factors, and these patients are then
offered to participate in the study if a diagnosis is made.
All GPs on the island of Funen using data capture [20]
in the spring of 2012 were invited to participate. Invita-
tions, startup meetings and monitoring of participating
GPs were handled by one study nurse (Figure 1). At the
startup meeting the participating GPs were given a binder
containing a standard operating procedure, including
protocols, questionnaires etc. Data capture is an electronic
system that captures data from the electronic patient
records (EPR) of participating GPs and transfers them
to the Danish General Practice Database (Figure 2). Data
collected automatically comprise all drug prescriptions, all
diagnoses of patient contacts, all disbursement codes and
all laboratory data recorded in the patient file. On the day
of the inclusion a pop-up will appear (Figure 3) and subse-
quently once a year, where the GP fills in questions about
COPD care. The participating GPs are also reminded to
reinvestigate COPD patients included by the project
nurse. The data from the fields in the pop-up are also
stored in the laboratory data.
The first practice to include patients started in October
2012. Since 2013 it is mandatory for Danish GPs to
participate in data capture. New practices starting to use
Figure 1 Schematic diagram of study. General practitioners working on Funen (500 000 inhabitants) were invited by the study nurse to
participate in the PROTECCT-M study if they were using data capture (Figure 2).
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by the study nurse. Currently (January 2014) 30 practices
with 77 GPs and 350 COPD patients have been recruited.
The study is planned to continue to include patients till
the end of 2016, but will continue to collect data on the
included patients through the data capture system after
the project period.
Study design
The PROTECCT-M study (Prognosis, Treatment and
Course of Events of COPD and the Use of BioMarkers)
is a prospective observational cohort study in primary
care on the island of Funen (approx. 500 000 inhabitants)
in Denmark. The decision to restrict the study to Funen
was made in order to secure quality of transport of blood
samples to Odense University Hospital.
The study is the primary care part of a collaborative
partnership with researchers interested in COPD at the
University of Southern Denmark, comprising researchers
also in molecular medicine, lung medicine and health
economics [17]. The group has a common funding from
the Danish Strategic Research Fund.
After the patient has been informed about the study
and signed an informed consent to participate, he/she is
invited to their usual GP for a baseline consultation, where
a pop-up menu in the EPR is filled in by the GP. ThisFigure 2 Data capture. The Sentinel Data Capture program collects key d
collected data are prescribed drugs, National Health Service disbursement
are collected via pop-up menu for specific diseases or conditions. Every nig
(DGPD), through the Sentinel Data Network (SDN). Treatment quality reporpop-up window is triggered by the ICPC R95 diagnosis
(Figure 3). The information collected by means of the
pop-up consists of all relevant indicators of the patient’s
COPD disease status, as recommended by the Danish
College of General Practitioners, and information con-
cerning lifestyle. During these consultations blood sam-
ples are collected and transferred to Odense University
Hospital, where the specimens are prepared and then
stored at the OPEN biobank [21] until analysis.
After the baseline consultation the patients are given a
questionnaire (including respiratory, quality of life and
activity of daily living questions), which they are asked
to fill in and send to the Research Unit of General Practice
using an attached prepaid envelope.
The participating GPs are encouraged to reinvestigate
included patients at least yearly after the baseline consult-
ation, and they get reminders both from the data capture
system and the research nurse. The data collected during
the yearly visits and also between visits are transferred
automatically by the data capture system and stored in the
Danish General Practice Research Database.
For specific research questions data will also be obtained
from Statistics Denmark, Odense Pharmacoepidemio-
logical Database (OPED), the National Patient Registry
(Landspatientregistret), the Danish Health Insurance
Registry and others.ata as it is entered into the GP´s electronic patient record system. The
codes, laboratory analysis results and ICPC diagnoses. In addition, data
ht data are sent to the Danish General Practice Research Database
ts are generated every weekend and can be accessed by the GPs.
Figure 3 Data collection. The PROTECCT-M COPD pop-up is displayed at the baseline visit and then once a year, when the GP enters an ICPC
diagnosis for COPD (R95-) in his electronic patient record system. The data is given as an example and is not from a real patient.
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ples collected during the baseline visits will be analysed
for SP-D and MFAP4 levels at the Institute of Medical
Biology, University of Southern Denmark, using the
funding already obtained.
Time schedule
All permissions are in place. The inclusion of patients is on-
going. The current project is planned to continue including
patients till the end of 2016. Using the data capture tech-
nology patient data can be collected continuously from the
specially developed COPD pop-up window and the GP´s
electronic patient record system after the project period.
Outcomes
The primary patient outcome is number of exacerbations.
The number of exacerbations during the preceding year
requiring antibiotic treatment or hospitalisation was re-
corded in the pop-up menu (Figure 3). The definition
of an exacerbation could be based on this or based on
prescribed treatment of antibiotics and/or corticosteroids
alone or in combination based on registers on prescribed
medication or hospitalisations due to infection or COPD.
Determinants of exacerbations
Demographic and clinical characteristics
Age
GenderComorbidity
Body mass index
Smoking status
Exacerbations during the preceding year
MRC, Medical Research Council Breathlessness Scale [22]
Educational level
Lung function
FEV1 – per 100 ml decrease
FEV1 – per 5% decrease in % of predicted value
GOLD stage – per increase to next stage
FEV1: FVC per 1% decrease
FVC – per 100 ml decrease
Patient-reported outcomes
CCQ, clinical COPD questionnaire [23]
SGRQ, St George Respiratory Questionnaire [24,25]
ADL, Activity of Daily Living, [26,27]
MDI, Major Depression Inventory [28]
MFI - 20, Multidimensional Fatigue Inventory [29,30]
Questions about lifestyle (smoking habits, dietary habits,
exercise, alcohol consumption) [31]
SF-12 [32]
EQ5D [33]
Biomarkers
Surfactant protein D (SP-D) [18,19]
Microfibrillar-associated protein 4 (MFAP4)
Søndergaard and Halling BMC Pulmonary Medicine 2014, 14:88 Page 5 of 6
http://www.biomedcentral.com/1471-2466/14/88Data analysis
Descriptive statistics will be generated for all variables.
Multivariate logistic regression models will be used to
determine variables independently associated with the
outcome variable. An analysis will be considered statisti-
cally significant at a probability level of p < 0.05 based on
two-sided tests.
Discussion
COPD is a common disease in the population, which is
often diagnosed and followed in primary care in the early
phases. COPD is a complex disease with both pulmonary
and extrapulmonary manifestations. Some patients deteri-
orate quickly, while others remain stable for a long period.
More accurate tools/markers, which can predict prognosis
and thus identify groups of patients in need of specific
therapies or rehabilitation are needed. COPD can be a
challenge to the GP since there are few tools to elucidate
the prognosis of the individual patient. For such tools
to be of “clinical utility” [34] it is of importance that the
evidence is generated in general practice under conditions
that resemble normal clinical practice as closely as pos-
sible, which we believe that data collection through data
capture offers. It is thus of importance that GPs are inter-
ested in participating in studies such as the present study
aiming at creating more personalised medicine for COPD
patients treated in primary care. The aim was to study
factors determining frequency of exacerbations and to
investigate if the biomarkers SP-D and MFAP4 have
such a role in COPD patients treated in primary care.
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